Many antiangiogenic therapies are designed to inhibit VEGF receptors or VEGF signaling in ECs, which results in the insufficient treatment of tumors and increased tumor metastasis due to elevated hypoxia in the tumor microenvironment [117]. The gene discussed is VEGFA; the disease is neoplasm.